PERformance of Multi-Cancer Early-detectIon Based on Various Biomarkers in fEmale Cancers, PERCEIVE-II

Inclusion Criteria for Cancer Arm Participants: * Age 18 years or older * Able to provide a written informed consent * Confirmed diagnosis or highly suspicious cases of gynecologic malignancies within 42 days prior to blood collection * No prior or ongoing anti-cancer therapy (local or systematic) prior to study blood draw Exclusion Criteria for Cancer Arm Participants: * Pregnancy or lactating women * Recipients of organ transplant or prior non-autologous (allogeneic) bone marrow transplant or stem cell transplant * Recipients of blood transfusion within 7 days prior to study blood draw * Recipients of any anti-cancer therapy within 30 days prior to study blood draw, due to diseases other than cancer. * previous history of malignant tumor; * precancerous lesions or benign diseases confirmed by biopsy or surgical specimen; * unknown or insufficient to determine the nature of the lesion by histopathological reports; Inclusion Criteria for healthy control Arm Participants: * Able to provide a written informed consent. * Able to provide sufficient and qualified blood samples for study tests. * No cancer related symptoms within 30 days prior to study screening. * Cancer history with curative treatment completed over 3 years without recurrence prior to study enrollment. Exclusion Criteria for healthy control Arm Participants: * Insufficient qualified blood sample for study test. * During pregnancy or lactation. * Recipient of organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant. * Recipient of blood transfusion within 30 days prior to study blood draw. * Recipient of anti-infectious therapy within 14 days prior to study blood draw. * Have received or are undergoing curative cancer treatment within three years prior to study screening. * With autoimmune or other diseases with severe comorbidities.